ALGS (Aligos Therapeutics) Short-term investments

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ALGS Aligos Therapeutics Inc ALGS
37 GF Score
Price $4.67
GF Value $2.76
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Aligos Therapeutics Short-term investments?

Short-term investments only applies to insurance companies.

ALGS
37GF Score
Aligos Therapeutics Inc ALGS
Short-term investments is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Aligos Therapeutics (ALGS) Overvalued in 2026?

Based on GuruFocus' analysis, Aligos Therapeutics stock appears to be overvalued. The current stock price of $4.67 is trading 69.2% above its estimated GF Value™ of $2.76. GuruFocus considers Aligos Therapeutics to be Significantly Overvalued.

Key valuation signals for ALGS:

  • Short-term investments:
  • GF Value™: $2.76 vs. price of $4.67 (69.2% above fair value)
  • GF Score™: 37/100 with 4 warning signs

No single metric tells the full story. See the ALGS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Aligos Therapeutics Business Description

Other Exchanges 5WK0:Germany
Address One Corporate Drive, 2nd Floor, South San Francisco, CA, USA, 94080
Aligos Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics for liver diseases and viral infections. Its pipeline includes drug candidates targeting chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and coronavirus infections, with programs such as pefivfoscorvir sodium for HBV, ALG-055009 for MASH and obesity, and ALG-097558 for coronavirus infections.
37GF Score

Get the complete analysis for ALGS

Short-term investments is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.67
Price
$2.76
GF Value